Over 1150 Total Lots Up For Auction at Three Locations - WI 07/09, NJ Cleansweep 07/10, CA 07/11

Johnson & Johnson Completes Omrix Buyout

by Lynn Shapiro, Writer | January 06, 2009
Omrix
Johnson & Johnson said it has completed its tender offer for shares of Omrix Biopharmaceuticals Inc., a New York-based maker of sealants used to control bleeding during surgery.

The $438 million acquisition, initially announced November 24, 2008, is meant to broaden J&J's Ethicon surgical products division. Before buying Omrix, J&J had been a backer of Omrix's technologies, including its experimental fibrin-based products being explored for tissue engineering and repair as well as soft tissue fixation, according to UBS investment analyst, Erik Schneider, who had given the company a "buy" rating.

J&J said Omrix shareholders tendered about 97.8 percent of shares in response to the J&J offer that expired on midnight, January 2, 2009. Remaining shares will be converted into the right to receive $25 in cash for each Omrix share.
stats
DOTmed text ad

Ensure critical devices are ready to go

Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.

stats Advertisement
Boards of both companies have approved the deal, as has the Israeli government. Omrix's manufacturing facilities are located in Tel Aviv.